Overview
This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients. To investigate the advancements in neurodegenerative diseases.
Description
This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients: a randomized, double-blind, placebo-controlled crossover design, and parallel clinical investigation.
Eligibility
Inclusion Criteria:
- Adults aged 30 to 70 years, whose native language is Chinese.
- Patients diagnosed with Spinocerebellar Ataxia.
- Subjects with a score below 30 on the Scale for the Assessment and Rating of Ataxia (SARA scale).
- Individuals who can read and write in Chinese and communicate in Chinese.
- Agree to participate in the study.
Exclusion Criteria:
- Patients with severe systemic diseases, such as heart or respiratory failure, liver or kidney failure, severe brain injury, prolonged bed rest, or incurable malignancies.
- Pregnant women and breastfeeding mothers.
- Patients who have taken Antrodia cinnamomea products within the last 6 months prior to the trial.
- Patients with other factors that prevent them from continuing to participate in this study.